UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Location
9 Ha'ta'asiya St, Ra'anana, Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597 % -15.1%
Quick Ratio 18.7 % -13.1%
Debt-to-equity -948 % -14.2%
Return On Equity 503 % +29.7%
Return On Assets -59.4 % -11.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.3M shares +9.85%
Common Stock, Shares, Outstanding 46.2M shares +12.2%
Entity Public Float 675M USD +255%
Common Stock, Value, Issued 126K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 47.7M shares +17.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 94.2M USD +10.9%
Cost of Revenue 10.8M USD +25.5%
Research and Development Expense 65M USD +24%
Operating Income (Loss) -124M USD -55.1%
Nonoperating Income (Expense) -688K USD -179%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -151M USD -37.6%
Income Tax Expense (Benefit) 4.15M USD +5.33%
Net Income (Loss) Attributable to Parent -155M USD -36.4%
Earnings Per Share, Basic -3 USD/shares -6.15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 92.9M USD -57.8%
Cash, Cash Equivalents, and Short-term Investments 162M USD -33%
Accounts Receivable, after Allowance for Credit Loss, Current 19.6M USD +12.8%
Inventory, Net 7.13M USD -4.22%
Assets, Current 197M USD -29.4%
Property, Plant and Equipment, Net 688K USD +18.6%
Operating Lease, Right-of-Use Asset 1.21M USD -3.2%
Other Assets, Noncurrent 801K USD +19%
Assets 209M USD -25.9%
Accounts Payable, Current 13.6M USD +63.1%
Employee-related Liabilities, Current 11.6M USD +70%
Liabilities, Current 47.5M USD +38.9%
Operating Lease, Liability, Noncurrent 552K USD +29.9%
Liabilities 302M USD +20.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 6K USD
Retained Earnings (Accumulated Deficit) -900M USD -20.8%
Stockholders' Equity Attributable to Parent -93.4M USD -408%
Liabilities and Equity 209M USD -25.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42M USD -32.4%
Net Cash Provided by (Used in) Financing Activities 54.7M USD +8046%
Net Cash Provided by (Used in) Investing Activities -26M USD -292%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 46.2M shares +12.2%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -68M USD -286%
Deferred Tax Assets, Valuation Allowance 169M USD +17.4%
Deferred Tax Assets, Gross 169M USD +17.7%
Operating Lease, Liability 1.22M USD -0.08%
Payments to Acquire Property, Plant, and Equipment 44K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -155M USD -36.6%
Lessee, Operating Lease, Liability, to be Paid 1.36M USD +3.97%
Property, Plant and Equipment, Gross 5.12M USD +8.38%
Operating Lease, Liability, Current 668K USD -16.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 305K USD +435%
Lessee, Operating Lease, Liability, to be Paid, Year One 364K USD -55.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +9.75%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 141K USD +60.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 229K USD
Deferred Tax Assets, Operating Loss Carryforwards 123M USD +18.7%
Unrecognized Tax Benefits 3.8M USD +18.8%
Operating Lease, Payments 220K USD -20.6%
Depreciation, Depletion and Amortization 278K USD -54.3%
Deferred Tax Assets, Net of Valuation Allowance 769K USD +140%
Share-based Payment Arrangement, Expense 12.6M USD +12.9%